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OBJECTIVE—Heterozygous mutations in the human preproin-
sulin (INS) gene are a cause of nonsyndromic neonatal or
early-infancy diabetes. Here, we sought to identify INS mutations
associated with maturity-onset diabetes of the young (MODY) or
nonautoimmune diabetes in mid-adult life, and to explore the
molecular mechanisms involved.
RESEARCH DESIGN AND METHODS—The INS gene was
sequenced in 16 French probands with unexplained MODY, 95
patients with nonautoimmune early-onset diabetes (diagnosed at
35 years) and 292 normoglycemic control subjects of French
origin. Three identiﬁed insulin mutants were generated by site-
directed mutagenesis of cDNA encoding a preproinsulin–green
ﬂuorescent protein (GFP) (C-peptide) chimera. Intracellular tar-
geting was assessed in clonal -cells by immunocytochemistry
and proinsulin secretion, by radioimmunoassay. Spliced XBP1
and C/EBP homologous protein were quantitated by real-time
PCR.
RESULTS—A novel coding mutation, L30M, potentially affecting
insulin multimerization, was identiﬁed in ﬁve diabetic individuals
(diabetes onset 17–36 years) in a single family. L30M preproin-
sulin-GFP ﬂuorescence largely associated with the endoplasmic
reticulum (ER) in MIN6 -cells, and ER exit was inhibited by
50%. Two additional mutants, R55C (at the B/C junction) and
R6H (in the signal peptide), were normally targeted to secretory
granules, but nonetheless caused substantial ER stress.
CONCLUSIONS—We describe three INS mutations cosegregat-
ing with early-onset diabetes whose clinical presentation is
compatible with MODY. These led to the production of (pre)pro-
insulin molecules with markedly different trafﬁcking properties
and effects on ER stress, demonstrating a range of molecular
defects in the -cell. Diabetes 59:653–661, 2010
M
isfolding of insulin, and consequently defec-
tive trafﬁcking to secretory granules, has
been recognized for a number of years as the
likely underlying cause of -cell dysfunction
and death in several rodent models of nonimmune diabe-
tes. These include the Akita mouse (1,2), in which a
heterozygous mutation in the Ins2 gene (CA7Y) disrupts
interchain disulphide bond formation leading to the en-
gorgement of the endoplasmic reticulum (ER) with mis-
folded proteins and ER stress. A similar mechanism
appears to pertain to the diabetic munich mouse, in which
intrachain disulphide bond formation is blocked by a C95S
mutation (3).
Mutations in the human preproinsulin (INS) gene were
ﬁrst identiﬁed more than 20 years ago (4–6) and although
some of these led to hyperproinsulinemia (7), none was
found to be associated with frank diabetes (4–7). More
recently, Støy et al. (8) described a group of patients
presenting with permanent neonatal diabetes or early
infancy–onset diabetes (median age at diagnosis of 13
weeks) who were carriers of a missense INS mutation.
Most of these mutations were novel, and three were
inherited in an autosomal dominant manner. Subse-
quently, we and three other reports (8–11) described
additional INS mutations linked to permanent neonatal
diabetes or nonautoimmune early infancy–onset diabetes.
The majority, although not all, of the mutations led to
diabetes onset in the ﬁrst 6 months of life (8–11). In vitro
analyses by Colombo et al. revealed that six of the
mutations identiﬁed led to ER retention in HEK293T cells
and to mild ER stress and at least two led to apoptosis (12).
Some of the INS mutations, including R6C (9) and A23S
(13) in the signal peptide, R46Q in the B chain, and R55C
at the B/C junction (11), were described with later ages at
diagnosis (up to 20 years), and these are presumed also to
cause insulin misfolding with consequent ER retention, an
unfolded protein response (UPR), and ER stress (2). Of
note, two individuals with the R55C mutation were diag-
nosed with diabetes at ages 10 and 13 years, both with
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ketoacidosis, but abundant circulating C-peptide levels
were detected in each case subject (11). The impact of
these mutations on protein folding, ER stress, and -cell
death has, until now, not been examined.
In this study, we aimed to determine the prevalence and
phenotype of INS mutations that may lead to diabetes at a
later age, including in maturity-onset diabetes of the young
(MODY), or in patients presenting with nonautoimmune
diabetes in mid-adult life (14). We describe here three
families with two novel and one previously described INS
mutations. The L30M mutation is predicted by structural
analysis in silico to be better tolerated within the insulin
hexamer than a previously described mutation at this
residue (L30P), which causes severe diabetes within the
ﬁrst 6 months of life (12). Thus, the L30M mutation was
associated with relatively mild diabetes (age at diagnosis
in the proband: 17 years). By confocal imaging of chimeric
insulin-GFP constructs in which GFP is fused in-frame
with C-peptide (plasmid hProCpepGFP) (15), we show
that this mutation causes clear insulin retention in the ER
and concomitant ER stress. By contrast, insulin-GFP bear-
ing the R6H mutation in the signal peptide exited the ER
normally and was properly targeted to secretory granules,
but induced signiﬁcant ER stress. The previously reported
R55C mutation (11), described here in a MODY family, was
also substantially retained in the ER in clonal -cells.
These ﬁndings reveal an unexpected divergence in the
effects of INS mutations at the molecular and cellular
level, with the clinical presentation and the severity of the
disease.
RESEARCH DESIGN AND METHODS
Subjects and mutation identiﬁcation. We studied 16 probands of French
families with clinically deﬁned MODY based on two criteria: diabetes diag-
nosed before age 25 years (range of age at diagnosis: 15–23) without
requirement of exogenous insulin in the ﬁrst 2 years, and an autosomal
dominant inheritance of type 2 diabetes (16). Of the 16 probands, 15 were
negative for a GCK/MODY-2 or HNF1A/MODY-3 mutation, and 8 were
negative for mutations in HNF4A/MODY-1, PDX1/MODY-4, and NEUROD1/
MODY-6, which were very rarely found in French MODY patients (16). All
patients with unexplained MODY were also negative for serologic markers of
type 1 diabetes. Ninety-ﬁve patients diagnosed with nonautoimmune diabetes
before age 35 years, and presenting with at least one affected ﬁrst-degree
relative (all are Caucasian and of French origin), were included in the study
for mutation identiﬁcation. In addition, we report functional studies on a R6H
mutation that was identiﬁed among 48 Danish patients with early-onset
diabetes and known vertical transmission of the disease (all tested negative
for a HNF4A/MODY-1, GCK/MODY-2, or HNF1A/MODY-3 mutation).
The three exons of the INS gene were screened for mutations from
genomic DNA of the patients by direct sequencing, as previously described
(10).
Additional members in three families (two French and one Danish), for
which an INS mutation was identiﬁed in the proband, were also screened for
the mutation (see RESULTS). Normoglycemic control subjects of French origin
(n  292) were also sequenced and all were found negative for the identiﬁed
mutations.
Assessment of clinical data. The clinical features of the patients carrying an
INS mutation, including age at onset and presentation of diabetes, and
information on past and current treatments for diabetes, have been reviewed.
In the family FR-AM, two subjects (the diabetic proband and his unaffected
mother) have undergone a measurement of body composition by dual energy
X-ray absorptiometry, and on a separate occasion, a euglycemic hyperinsu-
linemic clamp for the measurement of glucose uptake and a graded glucose
infusion for measurement of insulin secretory response. The proband’s
mother, who never developed diabetes and was normoglycemic at last
examination (after an oral glucose tolerance test [OGTT] at age 68 years), also
underwent an intravenous bolus of arginine at the end of the graded glucose
infusion to estimate her maximal insulin secretory capacity. Details of metabolic
studies are given in supplementary data, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-1091/DC1.
Proinsulin construct and generation of mutants. Human preproinsulin
cDNA cloned in pTARGET vector containing enhanced green ﬂuorescent
protein inserted in the C-peptide was kindly provided by Dr. Peter Arvan
(University of Michigan) (15). The single mutations (R6H, R6C, L30M, L30P,
and R55C) were inserted using a QuikChange II XL site-directed mutagenesis
kit (Stratagene, Agilent Technologies, Richardson, TX).
Proinsulin secretion assay. HEK293 cells (5  10
5/well) seeded on six-well
plates were transfected in triplicate with wild-type or mutant INS constructs
(4 g/well) using Lipofectamine2000 (Invitrogen, Carlsbad, CA). After 48 h,
normal growth media were replaced by 1 ml/well of reduced serum media
(Dulbecco’s modiﬁed Eagle’s medium, 2% FBS). After 20 h, human proinsulin
was measured in the supernatant by radioimmunoassay (Human Proinsulin
RIA; Millipore HPI-15K). Experiments were performed independently three
times.
Quantiﬁcation of transient expression of mRNA and protein. HEK293
cells were seeded and transfected as above. Samples for mRNA or protein
expression were collected after 48 h. Total RNA was extracted using Trizol
reagent (Invitrogen) and treated with DNA-free reagent (ABI Biosystems,
Foster City, CA) to remove any DNA contamination. RNA (2 g) was
reverse-transcribed using High-Capacity cDNA Reverse transcription kit (ABI
Biosystems). Real-time PCR was carried out with cDNA (equivalent of 20 ng
input RNA) using Power SYBR Green master mix (ABI Biosystems) in a 7500
Fast Real-Time PCR system (ABI Biosystems). All real-time primers (human
cyclophilin, insulin, and C/EBP homologous protein [CHOP]/GADD153) were
generated using ABI Primer Express 3.0. PCR ampliﬁcation of human XBP1
(X-box binding protein 1) was carried out with the cDNA equivalent of 100 ng
input RNA (see supplementary Table 1 for primer sequences).
For protein extraction, cells were washed twice in ice-cold PBS and lysed
in 1% Triton X-100 in PBS containing Complete protease inhibitor cocktail
(Roche Diagnostics). Total protein (30 g/well) was analyzed on 12% SDS–
polyacrylamide gels and transferred to polyvinylidene ﬂuoride membranes.
Blots were blocked with 5% nonfat milk in Tris-buffered saline for 1 h and,
subsequently, incubated 1 h for each, ﬁrst with primary antibody (monoclonal
anti-GFP, 1:1,000 [Sigma clone GSN24], monoclonal anti--tubulin, 1:10,000
[Sigma clone B-5–1–2]) followed by horseradish peroxidase–linked secondary
antibody (1:10,000; GE Healthcare), with 3 10-min washes with Tris-buffered
saline–0.1% Tween 20 between incubations. Blots were developed using ECL
Western blot detection reagent (GE Healthcare Life Sciences) and exposing to
Hyperﬁlm ECL (GE Healthcare Life Sciences).
Immunocytochemistry. MIN6 mouse pancreatic -cells (17) seeded on
poly-L-lysine–coated coverslips were transfected with wild-type or mutant
insulin constructs (4 g/well) with/without plasmid encoding DsRED-ER (2
g/well; Clontech) using Lipofectamine2000 and were allowed to overexpress
for 48 h. Cells coexpressing insulin granule marker were infected with
neuropeptide Y (NPY)-Venus virus (100 multiplicity of infection) (18) 24 h
after transfection with plasmids. Coverslips were washed twice with PBS,
ﬁxed in 4% paraformaldehyde (5 min), washed again, and mounted on slides
with Prolong gold (Invitrogen). Apoptosis was measured by staining trans-
fected cells for 5 min with annexin V–phycoerythrin before ﬁxation (Calbio-
chem, Merck Chemicals, Nottingham, U.K.). Cells were imaged using a Zeiss
Axiovert 200M microscope (Carl Zeiss, Jena, Germany) ﬁtted with a PlanApo
63 oil-immersion objective and a 1.5 Optivar attached to a Nokigawa
spinning disc confocal head. Samples were illuminated using steady-state
488-and 560-nm laser lines and emission was collected through ET535/30 and
ET620/60 emission ﬁlters (Chroma). Images were captured using a
Hamamatsu EM CCD digital camera, model C9100–13, controlled by an
Improvision/Nokigawa spinning disc system running Volocity software.
Data analysis and statistics. Statistical signiﬁcance was estimated using
ANOVA with Bonferroni multiple comparison test or paired t tests. Differ-
ences with at least P  0.05 were considered statistically signiﬁcant.
RESULTS
Identiﬁcation of INS mutations and clinical presen-
tation of diabetes. Three heterozygous missense INS
mutations were identiﬁed in two French and one Danish
patients diagnosed with nonautoimmune diabetes before
age 25 years. No further mutations were found by screen-
ing additional French probands with later onset familial
diabetes.
One novel mutation, a c.88CG-p.L30M change, was
found in a patient with diabetes diagnosed at 17 years of
age of normal body weight. This mutation was not present
in 292 nondiabetic control subjects of French origin.
Molecular modeling (Fig. 1A) revealed that this replace-
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more conservative than a previously described mutation at
the same site (L30P) (12) but, being located at the dimer
interface, may affect insulin multimerization (Fig. 1B and
C, see legend).
At diagnosis, the revealing symptom in the patient was
weight loss and the fasting glycemia was 16.5 mmol/l. No
autoimmunity against pancreas was detected, and the
pancreatic morphology (assessed by abdominal tomoden-
sitometry) was normal. Initially, glycemic control was
satisfactory with oral hypoglycemic agents (OHAs; gliben-
clamide associated to metformin). Subsequently, the asso-
ciation of various oral drugs proved insufﬁcient, and insulin
requirement occurred 9 years after diagnosis. A progres-
sive increase in insulin needs was observed during the
past 14 years (from 0.45 to 0.83 UI  kg
	1  day
	1), and A1C
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FIG. 1. Modeling of mutant insulin. Impact of L30M and L30P mutations on insulin folding (A) and hexamerization (B and C). A:
Energy-minimized models of insulin A and B chains, superimposed. (Left) wild type, green; L30M, red; (center) wild type, green, L30P, blue;
(right) L30M, red, L30P, blue. Homology models were built using Modeler9v4 software (http://www.salilab.org) using 1mso human insulin
structure as a template (30). B: Insulin hexamer showing L30 (L
B6) and H34 (H
B10) residues and Zn
2 (30). C and D: Close-up showing the impact
of L30M (L
B6M, center) and L30P (L
B6P, right) mutations in insulin B-chain versus wild type (left) showing the increased Cys-Cys distance,
disfavoring disulphide bond formation (C), and changes to the structure after disulphide bond formation (D). Leucine at position 6 of the B-chain
(L30) interacts with cysteine at position 6 of the A chain and leucine 17 and tryptophan 16 of the neighboring B-chain (B). L30M and L30P
mutations would therefore weaken or eliminate the interactions within the monomer and may also affect hexamer formation.
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giopathy was detected in this patient after 24 years of
diabetes evolution.
The L30M mutation cosegregated in ﬁve individuals
from the proband’s family with early-onset diabetes (range
of age at diagnosis: 17–38 years; range of BMI at last
examination: 19–25.5 kg/m
2; Fig. 2). However, the pro-
band’s mother was found to carry the mutation but was
not known to be diabetic, and had a normal OGTT at her
last examination at age 68 years (fasting and 2-h post–
glucose load glycemia of 5.1 and 7.6 mmol/l, respectively).
The other diabetic relatives were treated with OHA.
We also identiﬁed another MODY proband bearing a
c.163CT-p.R55C mutation at the B/C junction (previously
reported in a Norwegian case subject with apparent type 1
diabetes, but negative for autoantibodies [11]). The patient
was diagnosed with diabetes at age 9 years by signs of
polyuria and polydipsia, which required exogenous insulin
therapy at the time of diagnosis. After a follow-up of 50
years, clinical records indicated no signs of late-diabetic
complications (absence of retinopathy, nephropathy, or
cardiovascular disease) and a stable, well controlled gly-
cemic proﬁle (A1C ranges 6%). The mutation was found
to cosegregate with diabetes in two other diabetic rela-
tives, who were diagnosed at ages 37 (the mother) and 33
(the sister) years (Fig. 2). They were initially treated with
OHA, then with insulin therapy (12 and 5 years, respec-
tively, after their initial treatment). No complications of
diabetes were recorded from clinical evaluations of the
sister. The mother of the proband died at age 87 years (the
cause of death was not directly related to diabetes).
A c.17GA substitution, leading to a R6H change in the
signal peptide, was identiﬁed in a Danish proband (Fig. 2).
This patient was diagnosed with mild diabetes at age 20
years. He was treated with diet and OHA since diagnosis.
At age 50 years, he was treated with metformin (1 g  2),
A1C was 6.4%, fasting serum C-peptide was 419 pmol/l, and
fasting plasma glucose was 6.4 mmol/l. He had developed
retinopathy, neuropathy, and microalbuminuria. A brother
to the proband (M132–2 on Fig. 2), who also carries the
mutation, was diagnosed with diabetes at age 51 years. At
age 53 years, he was treated with diet alone and had no
signs of late-diabetic complications. A daughter of the
brother (M132–4 on Fig. 2), carrying the mutation, was
diagnosed with impaired glucose tolerance at age 26 years
and with gestational diabetes at age 27. After pregnancy,
she was treated with diet alone. She had no signs of
diabetes complications.
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FIG. 2. Pedigrees of the three probands identiﬁed with an INS mutation. The
symbols denote the following: solid symbols, diabetes status; striated symbol,
impaired glucose tolerance status; empty symbols, normoglycemic subjects; grid
symbol, one normal glucose tolerant subject who is carrier of the L30M mutation;
and gray symbols, subjects who were not available for genetic testing. Arrows
indicate the probands. The INS mutation status is shown under each symbol: NM
as heterozygote, NN as wild type, and NT as not tested. The text below indicates
the following: age at diagnosis of diabetes or age at examination in normoglyce-
mic subjects (in years), BMI (kg/m
2), and treatment in the diabetic subjects.
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mutation. As shown in Table 1, the diabetic proband
(family FR-AM) displayed a dramatic decrease in insulin
secretion during graded glucose infusion, whereas insulin
sensitivity measured during the euglycemic hyperinsuline-
mic clamp was normal; this is consistent with -cell failure
as the cause of diabetes. His nondiabetic mother was also
found to have a clear defect in insulin secretion, which was
apparent in response to both oral and intravenous glucose
load and also to the intravenous arginine test during hyper-
glycemia, raising the question as to why she did not develop
diabetes. Blood glucose level at 120 min during OGTT (7.6
mmol/l) was close to the glucose intolerance threshold (7.8
mmol/l). However, insulin sensitivity in this person must be
considered high, taking into account her age and her re-
ported high level of physical activity.
Impact of insulin mutations on intracellular trafﬁck-
ing ex vivo. We next examined the ability of the identiﬁed
mutations to affect insulin exit from the ER, initially using
HEK293 cells (12,15). These cells lack a well-deﬁned
regulated secretory pathway such that normal ER exit of a
proinsulin-GFP chimera (15) leads to the constitutive
release into the medium. Along with the three identiﬁed
mutations (R6H, L30M, R55C), two other previously re-
ported mutations, R6C (9) and L30P (12), were introduced
in the preproinsulin-GFP chimera (denoted henceforth as
PPI) for comparative molecular studies. Although all the
mutants expressed at similar levels to the wild-type at the
mRNA level (Fig. 3A), expressed protein levels in total cell
extract were lower in wild-type and R6H cells, most likely
reﬂecting the more efﬁcient constitutive secretion of these
molecules than the other mutant proteins (Fig. 3B). All
mutant proinsulin proteins migrated to same extent as wild-
type proinsulin on reducing SDS-PAGE, indicating efﬁcient
cleavage of preproinsulin signal peptide. When secreted
proinsulin was measured in the culture media, the L30M
mutant displayed a decrease in proinsulin release rate, albeit
less marked than that for the L30P mutant (Fig. 3C). In
contrast, secretion of R6H was not signiﬁcantly different
from wild type, although mutation to cysteine at the same
location (R6C) in the signal peptide led to substantially
compromised proinsulin release (Fig. 3C). The release of the
B/C junction mutant proinsulin, R55C, was also considerably
reduced (Fig. 3C), indicative of ER retention.
A large percentage of L30M (69 
 8%) and R55C (42 

3%) mutant chimera-expressing HEK293 cells displayed a
marked difference in the distribution of ﬂuorescence com-
pared with wild-type insulin GFP-expressing cells:
whereas ﬁne tubular/reticular ﬂuorescence, reminiscent of
a healthy ER (19), was evident in wild-type chimera-
expressing cells, a globular, perinuclear staining was usu-
ally apparent in cells expressing the L30M or R55C mutant
constructs (supplementary Figure 1). This observation is
consistent with retention of the mutant chimera in an
inﬂated and engorged ER.
To extend these ﬁndings to insulin-secreting cells, we
next expressed wild-type or mutant chimeras in clonal
MIN6 -cells (17). The ﬂuorescence of wild-type
hProCpepGFP was closely colocalized with the co-overex-
pressed secretory granule marker, neuropeptide Y-Venus
(Fig. 4) (18), with little or no colocalization with the
overexpressed ER marker, DsRed-ER (Fig. 5A). The insu-
lin-GFP ﬂuorescence distribution proﬁle along a straight
line drawn across one of the middle sections of individual
cells in Fig. 5A generates large peaks with intervals of low
ﬂuorescence zones (Fig. 5B), implying compacted storage
of protein in dense core vesicles and a lack of signiﬁcant
retention in the ER. By contrast, L30M chimera ﬂuores-
cence was barely detected in the NPY-Venus–positive
compartment (Fig. 4) but was strongly colocalized with
DsRed-ER, conﬁrming large-scale retention in the latter
organelle (Fig. 5A). The distribution of L30M was very
close to the structurally most perturbing mutation, L30P
(Fig. 1). On the other hand, R6H or R6C mutations in the
preproinsulin signal peptide appeared to exert no unto-
ward effects on proper folding within the ER (Fig. 5A), as
implied by appropriate vesicular targeting (Fig. 4) and as
conﬁrmed by a ﬂuorescence proﬁle similar to the wild-type
TABLE 1
Anthropometric and metabolic characteristics of two subjects (diabetic proband and nondiabetic mother from family FR-AM)
carrying the L30M-INS mutation, compared with a group of control subjects
Control group
Diabetic
proband
Nondiabetic
mother
n 18
Sex ratio (female/male) 10/8 Male Female
Age at examination (years) 26.8 
 6.6 40 68
BMI (kg/m
2) 22.9 
 3.3 25.9 21.7
OGTT
Fasting blood glucose (mmol/l) 4.6 
 0.3 7.2 5.1
Blood glucose at 120 min (mmol/l) 5.8 
 1.3 7.6
Fasting insulin (mUI/l) 5.5 
 3.8 2.4
Early insulin secretion (mUI/mmol) 16.9 
 10.7 2.3
Euglycemic hyperinsulinemic clamp
Body mass (%) 23.8 
 7.4 18.4 17.1
M value (mg  kg fat free mass
	1  min
	1) 10.9 
 2.4 9.1 9.4
Graded glucose infusion
Mean insulin secretion rate (pmol  kg
	1  min
	1) 8.80 
 3.70 0.66 1.19
Arginine test
Blood glucose at arginine injection (mmol/l) 20 
 2.9 25.6
Insulin AUC (mUI  5 min/l) 1,798.6 
 1,426.4 43.7
Incremental insulin (AUC insulin in mUI  5 min/l) 1,122.8 
 850.5 45.3
Data are means 
 SD. The M value is an estimate of insulin sensibility during the euglycemic hyperinsulinemic clamp. The control group
represents young adult subjects of French origin. AUC, area under the curve.
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an altered distribution pattern of insulin chimera with both
dense core vesicular targeting (Fig. 4A) as well as consid-
erable evidence of ER retention (Fig. 5A). The ﬂuores-
cence distribution proﬁle of L30M and R55C indicated
absence of peaks above the cutoff and a diffuse presence
throughout the ER (Fig. 5C). Furthermore, the total num-
ber of cells in a population of MIN6 -cells that produced
mutant insulin-containing granules signiﬁcantly decreased
in the presence of L30M and R55C mutants (Fig. 6),
consistent with either complete deﬁciency in the former or
attenuated insulin secretion in the latter (Fig. 3C).
Impact of insulin mutations on ER stress. Misfolded
client proteins accumulate in the ER to trigger an UPR that
initially upregulates ER chaperones but, in the longer
term, evokes cell death (20,21). The ER retention of L30P
and R55C mutants, a possible result of protein misfolding,
prompted us to examine whether they triggered UPR in
HEK293 cells by measuring the ER stress markers, XBP1
(12,22) and CHOP/GADD153 (23). Although the ER local-
ized sarco(endo)plasmic reticulum pump blocker, thapsi-
gargin, provoked enormous ER stress (24), indicated by
substantial accumulation of spliced XBP1 (Fig. 7A and B)
and CHOP/GADD153 mRNA (Fig. 7C), transfection with
the L30M, L30P, and R55C mutants also caused a moder-
ate, yet signiﬁcant increase of ER stress compared with
wild-type insulin. Interestingly, ER stress was also ob-
served in cells expressing the R6H mutant, as revealed by
enhanced expression of CHOP/GADD153, if not of spliced
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FIG. 3. Impact of insulin mutations on ER release and secretion in
HEK293 cells. A: Real-time PCR measurements of recombinant human
INS mRNA expression in transfected HEK293 cells normalized to
endogenous cyclophilin (means  SEM; n > 5). B: Typical Western blot
(n > 5) of total protein (30 g/lane) from HEK293 cells transfected or
not with INS constructs separated on 12% reducing SDS-PAGE and
probed ﬁrst with anti-GFP antibody, followed by -tubulin as loading
control. C: Secreted proinsulin content in 1 ml media of transfected
HEK293 cells collected for a period of 20 h (means  SEM; n > 5). No
secretion recorded for empty spaces. Data were analyzed by ANOVA
with Bonferroni multiple comparison test. ***P < 0.001.
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FIG. 4. Subcellular targeting of INS mutants to the dense core secre-
tory vesicles. MIN6 -cells transfected with mutant INS-GFP con-
structs were subsequently (typically after 24 h) infected with
adenoviral vector expressing NPY-cherry, a dense core vesicle marker.
Protein expression after 48 h was studied under 63 oil-immersion
lens of confocal microscope using 488-and 568-nm laser lines. Images
shown are of single cells (n > 25) with typical distribution of INS
mutant proteins. Note that the R6H panel captured two overlapping
cells expressing the R6H mutant in same focal plane, but only the top
one expressed NPY-cherry. Scale bar, 7 m. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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mutant preproinsulin, but not proinsulin or mature insulin,
differed from the corresponding wild-type proteins. De-
spite elevated ER stress marker levels, under these exper-
imental conditions none of the three new mutants evoked
any signiﬁcant apoptotic cell death that could be detected
with annexin V staining of HEK293 cells (data not shown).
DISCUSSION
More than 25 separate mutations in the human INS gene
have been described, leading to very early-onset diabetes
diagnosed in the neonatal period or early infancy in most
case subjects, but also later in childhood or in young
adulthood (25). Our study from two European cohorts of
diabetic patients diagnosed with MODY conﬁrms that
coding INS mutations are also associated with the MODY
form of diabetes, albeit with a much lower prevalence
compared with the MODY-2/GCK and MODY-3/HNF1A
subtypes. Moreover, our description of three families with
three separate mutations highlights a great variability in
clinical presentation, as well as in the severity and evolu-
tion of diabetes, even between carriers of the same
mutation within a family.
Several of the INS mutations leading to the most pro-
found pathologies (i.e., neonatal diabetes) involve the
appearance of an insulin molecule with an unpaired cys-
teine residue, as observed in Akita (1) and munich (3)
mice, and cause a severe folding defect, UPR, and -cell
apoptosis. Human INS mutations at position 6 of the
B-chain, L30P or L30V, have previously been found to
cause early-infancy diabetes (12). These mutants were
shown to be substantially retained in the ER and lead to
abnormal splicing of XBP1, implying a folding defect and
an increased ER stress response. However, the behavior
and trafﬁcking of these mutants in insulin-secreting cells
has not previously been described.
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FIG. 5. ER retention caused by INS mutations and distribution of INS-GFP mutant proteins within single clonal -cells. A: MIN6 -cells
cotransfected with DsRED-ER, an ER marker along with INS-GFP constructs and protein expression was studied after 48 h, as in Fig. 4. Scale bar,
7 m. B and C: Green ﬂuorescence was measured (in absolute gray values) across a line drawn through middle section of typical transfected MIN6
cells and the proﬁle plotted against distance in pixels. The gray broken line limits a cutoff ﬂuorescence intensity to differentiate local
accumulation of high concentrations of insulin in vesicles compared with diffused appearance across ER. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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novel mutation, led to a milder clinical presentation (dia-
betes onset at 17–38 years) despite clear ER retention and
evidence of UPR (Figs. 3–5). Although the presence of a
methionine at this site is likely to lead to a smaller change
in the structure around the hydrophobic core than proline
(Fig. 1A), the location of L30 at the dimer-dimer interface
(Fig. 1B and C) might affect the formation of insulin
multimers. Although insulin hexamerization and conden-
sation are generally thought to occur in the trans-Golgi and
in immature granules, it seems conceivable that defective
dimer association may occur earlier in the secretory
pathway and hence inﬂuence exit from the ER of the
mutant. Such a model would be consistent with the L30M
mutant prompting a UPR. Importantly, the more substan-
tial vesicular targeting of the L30M than the L30P mutant
in MIN6 cells (Fig. 6) suggests that ER exit is more efﬁcient
for the former, even though secretion of proinsulin from
HEK293 cells was below the level of detection with either
mutant (Fig. 3C). Nonetheless, this difference presumably
permits more sustained insulin secretion in early life for
L30M mutant carriers, with less marked -cell loss and hence
a later onset of diabetes than those carrying L30P, and leads
to marked phenotypic differences within one family.
Interestingly, the novel mutation R6H barely affected
proinsulin release or ER stress, as assessed by XBP1
splicing, and yet prompted the largest induction of CHOP
mRNA of all the mutants examined. Because human
preproinsulin contains a signal peptide with a classical
tripartite domain structure, that is, a positively charged
NH2-terminal (n-), a hydrophobic core (h-), and a COOH-
terminal polar domain (c-region), and because the h-and
c-regions determine processing of signal peptide (26), the
R6H mutation in the n-region should not affect signal
peptide cleavage. However, a shift in net positive charge at
cellular pH in the n-region due to replacement of arginine
(acid dissociation constant, 12.5) by histidine (acid disso-
ciation constant, 6–6.5) may inﬂuence both the level of
protein translation and efﬁciency of export (27). This in
turn may cause mild ER stress sufﬁcient to prompt CHOP
activation (28), perhaps by activating PERK, although
IRE1 activity and thus XBP1 splicing are unaffected.
Whatever the underlying mechanisms are, these data indi-
cate that this mutation in the preproinsulin signal peptide
leads to a distinct form of UPR/ER stress response com-
pared with mutants in the mature insulin molecule, which
seems likely to impact on -cell survival in vivo, as
suggested by the clinical presentation of diabetes in the
Danish family. The R6H mutant thus acts somewhat dif-
ferently to the previously described R6C mutation (9) (Fig.
7C), causing more limited -cell loss or dysfunction (29).
Although we cannot exclude the possibility that the
behavior of the proinsulin mutants in the cell culture
systems used here may differ from that of the mutants in
human -cells in vivo, earlier observations also support
the above view that the molecular mechanisms underlying
diabetes in carriers of different INS mutations may differ.
Thus, Molven et al. (11) reported abundant C-peptide in
two carriers of the R55C mutation, implying a substantially
retained -cell mass and normal insulin release, despite
hyperglycemia and ketoacidosis at presentation. However,
split proinsulin may also have contributed to the apparent
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FIG. 7. ER stress markers induced by INS mutants. HEK293 cells were
either transfected with INS mutants allowing 48 h for protein expres-
sion or treated with 100 nmol/l thapsigargin (Tg) for 4 h, and total RNA
was extracted. After reverse transcription, 2 g RNA was ampliﬁed
either by conventional PCR (100 ng cDNA) or by real-time PCR (20 ng
cDNA). A: Typical agarose gel (2%) separated with Tris-borate-EDTA
(TBE) buffer showing spliced (S) and unspliced (U) forms of PCR-
ampliﬁed XBP1 cDNA. B: Quantiﬁcation of spliced form of XBP1. The
gray values of the bands (as in A) of spliced and unspliced XBP1
quantiﬁed (means  SEM; n  3). C: Real-time quantiﬁcation of
CHOP/GADD153 mRNA normalized to endogenous cyclophilin
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sulin mutant is unlikely to be fully processed by car-
boxypeptidase E, the presence of an unpaired cysteine
may prompt a UPR. Of note, the previously identiﬁed R89C
mutation at the C-A junction led to a dramatic decrease in
C-peptide levels in two patients with neonatal diabetes,
suggesting massive -cell loss (12).
In summary, we show that mutations in the human
preproinsulin gene are a cause of nonautoimmune diabetes
with variable clinical features at presentation in early life or
in young adulthood, and also in the long-term evolution. Our
ﬁndings suggest that the degree of ER retention, and the
nature of the UPR, can differ widely between mutants,
generating a range of underlying -cell defects.
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